-
Merck Announces Promising One-Year Results for Remigromig in Phase 2b/3 Brunello Study
NYSE: $MRK A New Frontier in Autoimmune Research Merck has officially shared positive one-year results from its pivotal Phase 2b/3 Brunello clinical trial. The study is evaluating the safety and efficacy of remigromig, an investigational anti-PD-1 therapy, specifically targeting patients living with moderate-to-severe systemic lupus erythematosus (SLE). Understanding the Brunello Study The Brunello trial is…
-
A New Frontier in Cancer Research: Understanding Merck’s Remigromig
NYSE: $MRK Targeting the Wnt Pathway In a significant move for oncology research, Merck has initiated a Phase 1 clinical trial to evaluate its investigational agent, remigromig. This novel therapy represents a sophisticated approach to cancer treatment, specifically designed as a tri-specific agonist of the Wingless-related integration site (Wnt) pathway. What is Remigromig? Remigromig is…